An update on the use of surfactant in neonates

Current Paediatrics

Volumn 14, Issue 4, 2004, Pages 284-289

  McDonald, Craig L ^a   Ainsworth, Sean B ^a  

^a NHS FIFE   (United Kingdom)

Author keywords

Bronchiolitis; Meconium aspiration syndrome; Pneumonia; Pulmonary haemorrhage; Pulmonary surfactant; Respiratory distress syndrome

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; HL 10; LUCINACTANT; LUSUPULTIDE; PORACTANT; PUMACTANT; SURFACTANT; UNCLASSIFIED DRUG;

BOLUS INJECTION; BRONCHIOLITIS; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL DIAPHRAGM HERNIA; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG UTILIZATION; GENETIC ASSOCIATION; HUMAN; LUNG ALVEOLUS SURFACE TENSION; LUNG DISEASE; LUNG FUNCTION; LUNG HEMORRHAGE; LUNG VENTILATION; MECONIUM ASPIRATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; OUTCOMES RESEARCH; OXYGENATION; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PROPHYLAXIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SEPSIS; TREATMENT INDICATION;

EID: 3242661748     PISSN: 09575839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cupe.2004.04.004     Document Type: Article

References (40)

1. Weaver T.E., Conkright J.J. Function of surfactant proteins B and C. Ann Rev Physiol. 63:2001;555-578
2. Crouch E., Wright J.R. Surfactant proteins A and D and pulmonary host defense. Ann Rev Physiol. 63:2001;521-554
3. Cochrane C.G., Revak S.D., Merritt T.A., et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med. 153:1996;404-410
4. Hafner D., Beume R., Kilian U., et al. Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). Br J Pharmacol. 115:1995;451-458
5. Walther F.J., David-Cu R., Leung C., et al. A synthetic segment of surfactant protein A. structure, in vitro surface activity, and in vivo efficacy Pediatr Res. 39:1996;938-946
6. Clark H., Palaniyar N., Strong P., et al. Surfactant protein D reduces alveolar macrophage apoptosis in vivo. J Immunol. 169:2002;2892-2899
7. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: Wiley; 2003.
8. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: Wiley; 2003.
9. Sinn J.K., Ward M.C., Henderson-Smart D.J. Developmental outcome of preterm infants after surfactant therapy. systematic review of randomized controlled trials J Paediatr Child Health. 38:2002;597-600
10. Takahashi A., Nemoto T., Fujiwara T. Biophysical properties of protein-free, totally synthetic surfactants, ALEC and Exosurf, in comparison with Surfactant TA. Acta Pediatr Jpn. 36:1994;613-618
11. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: Wiley; 2003.
12. ® for prevention of RDS in very preterm babies [abstract]. Pediatr Res. 54:2003;587
13. Speer C.P., Gefeller O., Groneck P., et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 72:1995;F8-F13
14. Ramanathan R, Ramussen MR, Gerstmann D, Finer N, Sekar K. and The North American Study Group. A randomized, multicenter masked comparison trial of Poractant alfa Curosurf® and beractant Survanta® in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21:109-19.
15. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: Wiley; 2003.
16. Hallman M., Merritt T.A., Pohjavuori M., Gluck L. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome. evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure Pediatr Res. 20:1986;1228-1235
17. Berry D.D., Pramanik A.K., Philips J.B., et al. Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing ≥1250 grams with respiratory distress syndrome. American Exosurf Neonatal Study Group II. J Pediatr. 124:1994;294-301
18. Halliday H.L., Tarnow-Mordi W.O., Corcoran J.D., Patterson C.C. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child. 69:1993;276-280
19. Corbet A., Gerdes J., Long W., et al. Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100. grams effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa J Pediatr. 126:1995;969-978
20. Anonymous. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency - the role of surfactant). Lancet 1992;340:1363-9.
21. van der Bleek J., Plotz F.B., van Overbeek F.M., et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure. the effect of volume Pediatr Res. 34:1993;154-158
22. Lewis J.F., Ikegami M., Jobe A.H., et al. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. Am Rev Respir Dis. 147:1993;1364-1370
23. Berggren E., Liljedahl M., Winbladh B., et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 89:2000;460-464
24. Jorch G., Hartl H., Roth B., et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol. 24:1997;222-224
25. Van Marter L.J., Allred E.N., Pagano M., et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics. 105:2000;1194-1201
26. Ho JJ, Subramaniam P, Henderson-Smart DJ, Davis PG. Continuous distending pressure for respiratory distress syndrome in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: Wiley; 2003.
27. Thomson M.A. Early nasal continuous positive airways pressure (nCPAP) with prophylactic surfactant for neonates at risk of RDS. The IFDAS Multi-Centre Randomised Trial. [abstract] Arch Dis Child. 86(Suppl 1):2002;8
28. Dargaville P.A., South M., McDougall P.N. Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr. 138:2001;113-115
29. Sun B., Curstedt T., Song G.W., Robertson B. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate. 63:1993;96-104
30. Lotze A., Mitchell B.R., Bulas D.I., et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in term infants study group. J Pediatr. 132:1998;40-47
31. Findlay R.D., Taeusch H.W., Walther F.J. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics. 97:1996;48-52
32. Walther F.J., Hernandez-Juviel J., Bruni R., Waring A.J. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Am J Respir Crit Care Med. 156:1997;855-861
33. Wiswell T.E., Knight G.R., Finer N.N., et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics. 109:2002;1081-1087
34. Lu K.W., Taeusch H.W., Robertson B., et al. Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med. 162:2000;623-628
35. Devendra G., Spragg R.G. Lung surfactant in subacute pulmonary disease. Respir Res. 3:2002;19. (available at http://respiratory-research.com/content/3/ 1/19)
36. Herting E., Sun B., Jarstrand C., et al. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Child Fetal Neonatal Ed. 76:1997;F3-F8
37. Herting E., Gefeller O., Land M., et al. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics. 106:2000;957-964
38. Haroon M. Can surfactant cure babies with severe bronchiolitis? Arch Dis Child. 88:2003;834-835
39. Lally K.P. Congenital diaphragmatic hernia. Curr Opin Pediatr. 14:2002;486-490
40. Papworth S., Cartlidge P.H. Pulmonary haemorrhage. Curr Paediatr. 11:2001;167-171